Načítá se...
Bilirubin, a new therapeutic for kidney transplant?
In patients with end-stage renal disease, kidney transplantation has been associated with numerous benefits, including increased daily activity, and better survival rates. However, over 20% of kidney transplants result in rejection within five years. Rejection is primarily due to a hypersensitive im...
Uloženo v:
| Vydáno v: | Transplant Rev (Orlando) |
|---|---|
| Hlavní autoři: | , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6535229/ https://ncbi.nlm.nih.gov/pubmed/29983261 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.trre.2018.06.003 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|